AC Immune reports favorable Phase 1 data for ACI-19764
AC Immune SA said early Phase 1 results for ACI-19764 showed the orally administered NLRP3 inflammasome drug was safe and well tolerated, with brain penetration and dose-dependent IL-1beta inhibition.